tables summarize total stock-based compensation expense included on our Consolidated Statements of Operations, classified by award type and expense type:
_______________________________
(1)
Accelerated post-acquisition stock-based compensation expenses of $
133
million related to the 2024 CymaBay acquisition, $
19
million and $
10
million related to the 2023 XinThera and Tmunity acquisitions, respectively, and
$
8
million
related to the 2022 MiroBio acquisition.
RSUs
We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over
three
or
four years
from the date of grant. RSUs have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.
88
The following tables summarize our RSU activity:
As of December 31, 2024, there was $
1.1
billion of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of
2.2
years.
PSUs
We grant PSUs that vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from
0
% to
200
%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. PSUs have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.
The following tables summarize our PSU activity:
As of December 31, 2024, there was $
31
million of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of
1.1
years.
Stock Options
Option grants are designated as either non-statutory or incentive stock options. The exercise price of stock options may not be less than the fair market value of our common stock on the grant date and no stock option may have a term in excess of
10
years. Employee stock options generally vest over
three
or
four years
. Stock options may be settled in cash or in shares of our common stock, including a net issuance using shares otherwise purchasable under the option to pay the exercise price.
89
The following tables summarize activity and other information related to our stock options:
_______________________________
(1)
Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or